Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magdalena Ritter

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Breast Cancer (Dove Medical Press)|July 24, 2023
PRO Hair Safe Study: The Patient's Perspective on the Effects of Scalp Cooling on Hair PreservationChristine Brunner, Daniel Egle, Magdalena Ritter, et al.
European Journal of Cancer (Oxford, England : 1990)|January 2, 2023
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12Ana-Alicia Beltran-Bless, Mark J Clemons, Christian Fesl, et al.
NEJM Evidence|February 6, 2024
Long-Term Outcomes of Adjuvant Denosumab in Breast CancerMichael Gnant, Sophie Frantal, Georg Pfeiler, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Breast Cancer (Dove Medical Press)|July 24, 2023
PRO Hair Safe Study: The Patient's Perspective on the Effects of Scalp Cooling on Hair PreservationChristine Brunner, Daniel Egle, Magdalena Ritter, et al.
European Journal of Cancer (Oxford, England : 1990)|January 2, 2023
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12Ana-Alicia Beltran-Bless, Mark J Clemons, Christian Fesl, et al.
NEJM Evidence|February 6, 2024
Long-Term Outcomes of Adjuvant Denosumab in Breast CancerMichael Gnant, Sophie Frantal, Georg Pfeiler, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
Pageof 2